Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC

INTRODUCTION: In the phase 3 KEYNOTE-604 study (NCT03066778), pembrolizumab plus etoposide and platinum chemotherapy (EP) significantly (p = 0.0023) improved progression-free survival versus placebo plus EP in previously untreated extensive-stage SCLC (ES-SCLC). We present health-related quality of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hye Ryun, Awad, Mark M., Navarro, Alejandro, Gottfried, Maya, Peters, Solange, Csőszi, Tibor, Cheema, Parneet K., Rodriguez-Abreu, Delvys, Wollner, Mirjana, Yang, James Chih-Hsin, Mazieres, Julien, Orlandi, Francisco J., Luft, Alexander, Gümüş, Mahmut, Kato, Terufumi, Kalemkerian, Gregory P., Luo, Yiwen, Santorelli, Melissa L., Pietanza, M. Catherine, Rudin, Charles M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637979/
https://www.ncbi.nlm.nih.gov/pubmed/37954964
http://dx.doi.org/10.1016/j.jtocrr.2023.100572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637979/
https://www.ncbi.nlm.nih.gov/pubmed/37954964
http://dx.doi.org/10.1016/j.jtocrr.2023.100572

Ejemplares similares